NCT02754830View on ClinicalTrials.gov

A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

April 25, 2016

Primary Completion Date

July 10, 2018

Study Completion Date

July 10, 2018

Conditions
Alzheimer's Disease
Interventions
DRUG

LY3303560 - IV

Administered IV

DRUG

Saline Solution - IV

Administered IV

DRUG

LY3303560 - SC

Administered SC

Trial Locations (2)

21225

PAREXEL-Phase 1 Baltimore Harbor Hospital Center, Baltimore

91206

Parexel Early Phase Unit at Glendale, Glendale

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02754830 - A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD) | Biotech Hunter | Biotech Hunter